A retrospective review was conducted to assess the effect of various interventions on inappropriate prescribing of acid-suppressive agents in the hospital. Providing educational lectures was helpful, but adding a pharmacist to the health care team resulted in the greatest decline in inappropriate use of these drugs.
You are here
Interventions to Curb the Overuse of Acid-Suppressive Medications on an Inpatient General Medicine Service
Implications for Prescribing Practice and Therapeutic Interchange
Although low-molecular-weight heparins (LMWHs) have similar antithrombotic effects, they differ in their pharmacological and biochemical profiles. The authors discuss therapeutic interchange programs for currently available LMWHs and the risks to patients when agents are not clinically interchangeable.
Drugs discussed include dasatinib (Sprycel), nilotinib (Tasigna), and imatinib (Gleevec) for patients with chronic myelogenous leukemia; deferasirox (Exjade) for beta-thalassemia major with iron overload; eculizumab (Soliris) for thrombocytopenia; and romiplostim (Nplate) for myelodysplastic syndromes.
Topics include an influenza vaccine (Fluzone High-Dose) to prevent virus subtypes A and B in older patients; von Willebrand factor/coagulation factor VIII complex (Wilate) to treat spontaneous and trauma-induced bleeding in patients with von Willebrand’s disease; and tranexamic acid (Lysteda) for heavy menstrual bleeding.